Search Results - "Oscier, D"

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial by Catovsky, D, Prof, Richards, S, DPhil, Matutes, E, FRCPath, Oscier, D, FRCP, Dyer, MJS, Prof, Bezares, RF, MD, Pettitt, AR, Prof, Hamblin, T, Prof, Milligan, DW, FRCP, Child, JA, Prof, Hamilton, MS, FRCP, Dearden, CE, FRCP, Smith, AG, FRCP, Bosanquet, AG, PhD, Davis, Z, MSc, Brito-Babapulle, V, PhD, Else, M, MSc, Wade, R, MSc, Hillmen, P, FRCP

“…Summary Background Previous studies of patients with chronic lymphocytic leukaemia reported high response rates to fludarabine combined with cyclophosphamide…”
Get full text

Recurrent mutations refine prognosis in chronic lymphocytic leukemia by Baliakas, P, Hadzidimitriou, A, Sutton, L-A, Rossi, D, Minga, E, Villamor, N, Larrayoz, M, Kminkova, J, Agathangelidis, A, Davis, Z, Tausch, E, Stalika, E, Kantorova, B, Mansouri, L, Scarfò, L, Cortese, D, Navrkalova, V, Rose-Zerilli, M J J, Smedby, K E, Juliusson, G, Anagnostopoulos, A, Makris, A M, Navarro, A, Delgado, J, Oscier, D, Belessi, C, Stilgenbauer, S, Ghia, P, Pospisilova, S, Gaidano, G, Campo, E, Strefford, J C, Stamatopoulos, K, Rosenquist, R

“…Through the European Research Initiative on chronic lymphocytic leukemia (CLL) (ERIC), we screened 3490 patients with CLL for mutations within the NOTCH1 ( n…”
Get full text

Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation by Martínez, N, Almaraz, C, Vaqué, J P, Varela, I, Derdak, S, Beltran, S, Mollejo, M, Campos-Martin, Y, Agueda, L, Rinaldi, A, Kwee, I, Gut, M, Blanc, J, Oscier, D, Strefford, J C, Martinez-Lopez, J, Salar, A, Sole, F, Rodriguez-Peralto, J L, Diez-Tascón, C, García, J F, Fraga, M, Sebastián, E, Alvés, J, Menárguez, J, González-Carreró, J, Casado, L F, Bayes, M, Bertoni, F, Gut, I, Piris, M A

“…Splenic marginal zone lymphoma (SMZL) is a B-cell neoplasm whose molecular pathogenesis remains fundamentally unexplained, requiring more precise diagnostic…”
Get full text

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia by Young, E, Noerenberg, D, Mansouri, L, Ljungström, V, Frick, M, Sutton, L-A, Blakemore, S J, Galan-Sousa, J, Plevova, K, Baliakas, P, Rossi, D, Clifford, R, Roos-Weil, D, Navrkalova, V, Dörken, B, Schmitt, C A, Smedby, K E, Juliusson, G, Giacopelli, B, Blachly, J S, Belessi, C, Panagiotidis, P, Chiorazzi, N, Davi, F, Langerak, A W, Oscier, D, Schuh, A, Gaidano, G, Ghia, P, Xu, W, Fan, L, Bernard, O A, Nguyen-Khac, F, Rassenti, L, Li, J, Kipps, T J, Stamatopoulos, K, Pospisilova, S, Zenz, T, Oakes, C C, Strefford, J C, Rosenquist, R, Damm, F

“…Recurrent mutations within EGR2 were recently reported in advanced-stage chronic lymphocytic leukemia (CLL) patients and associated with a worse outcome. To…”
Get full text

KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype by Clipson, A, Wang, M, de Leval, L, Ashton-Key, M, Wotherspoon, A, Vassiliou, G, Bolli, N, Grove, C, Moody, S, Escudero-Ibarz, L, Gundem, G, Brugger, K, Xue, X, Mi, E, Bench, A, Scott, M, Liu, H, Follows, G, Robles, E F, Martinez-Climent, J A, Oscier, D, Watkins, A J, Du, M-Q

“…To characterise the genetics of splenic marginal zone lymphoma (SMZL), we performed whole exome sequencing of 16 cases and identified novel recurrent…”
Get full text

Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2 by Strefford, J C, Sutton, L-A, Baliakas, P, Agathangelidis, A, Malčíková, J, Plevova, K, Scarfó, L, Davis, Z, Stalika, E, Cortese, D, Cahill, N, Pedersen, L B, di Celle, P F, Tzenou, T, Geisler, C, Panagiotidis, P, Langerak, A W, Chiorazzi, N, Pospisilova, S, Oscier, D, Davi, F, Belessi, C, Mansouri, L, Ghia, P, Stamatopoulos, K, Rosenquist, R

“…Recent studies have revealed recurrent mutations of the NOTCH1 , SF3B1 and BIRC3 genes in chronic lymphocytic leukemia (CLL), especially among aggressive,…”
Get full text

The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1 by Larrayoz, M, Blakemore, S J, Dobson, R C, Blunt, M D, Rose-Zerilli, M J J, Walewska, R, Duncombe, A, Oscier, D, Koide, K, Forconi, F, Packham, G, Yoshida, M, Cragg, M S, Strefford, J C, Steele, A J

“…The pro-survival Bcl-2 family member Mcl-1 is expressed in chronic lymphocytic leukaemia (CLL), with high expression correlated with progressive disease. The…”
Get full text

13q deletion anatomy and disease progression in patients with chronic lymphocytic leukemia by Parker, H, Rose-Zerilli, M J J, Parker, A, Chaplin, T, Wade, R, Gardiner, A, Griffiths, M, Collins, A, Young, B D, Oscier, D G, Strefford, J C

“…Historically, genes targeted by recurrent chromosomal deletions have been identified within the smallest genomic region shared in all patients, the minimally…”
Get full text

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria by Matutes, E, Oscier, D, Montalban, C, Berger, F, Callet-Bauchu, E, Dogan, A, Felman, P, Franco, V, Iannitto, E, Mollejo, M, Papadaki, T, Remstein, E D, Salar, A, Solé, F, Stamatopoulos, K, Thieblemont, C, Traverse-Glehen, A, Wotherspoon, A, Coiffier, B, Piris, M A

“…Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL…”
Get full text

Telomere length predicts progression and overall survival in chronic lymphocytic leukemia: data from the UK LRF CLL4 trial by Strefford, J C, Kadalayil, L, Forster, J, Rose-Zerilli, M J J, Parker, A, Lin, T T, Heppel, N, Norris, K, Gardiner, A, Davies, Z, Gonzalez de Castro, D, Else, M, Steele, A J, Parker, H, Stankovic, T, Pepper, C, Fegan, C, Baird, D, Collins, A, Catovsky, D, Oscier, D G

Get full text

Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors by Sutton, Lesley-Ann, Young, Emma, Baliakas, Panagiotis, Hadzidimitriou, Anastasia, Moysiadis, Theodoros, Plevova, Karla, Rossi, Davide, Kminkova, Jana, Stalika, Evangelia, Pedersen, Lone Bredo, Malcikova, Jitka, Agathangelidis, Andreas, Davis, Zadie, Mansouri, Larry, Scarfò, Lydia, Boudjoghra, Myriam, Navarro, Alba, Muggen, Alice F, Yan, Xiao-Jie, Nguyen-Khac, Florence, Larrayoz, Marta, Panagiotidis, Panagiotis, Chiorazzi, Nicholas, Niemann, Carsten Utoft, Belessi, Chrysoula, Campo, Elias, Strefford, Jonathan C, Langerak, Anton W, Oscier, David, Gaidano, Gianluca, Pospisilova, Sarka, Davi, Frederic, Ghia, Paolo, Stamatopoulos, Kostas, Rosenquist, Richard

“…We report on markedly different frequencies of genetic lesions within subsets of chronic lymphocytic leukemia patients carrying mutated or unmutated…”
Get full text

Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia by Knight, S J L, Yau, C, Clifford, R, Timbs, A T, Sadighi Akha, E, Dréau, H M, Burns, A, Ciria, C, Oscier, D G, Pettitt, A R, Dutton, S, Holmes, C C, Taylor, J, Cazier, J-B, Schuh, A

“…Genome-wide array approaches and sequencing analyses are powerful tools for identifying genetic aberrations in cancers, including leukemias and lymphomas…”
Get full text

Non-coding NOTCH1 mutations in chronic lymphocytic leukemia; their clinical impact in the UK CLL4 trial by Larrayoz, M, Rose-Zerilli, M J J, Kadalayil, L, Parker, H, Blakemore, S, Forster, J, Davis, Z, Steele, A J, Collins, A, Else, M, Catovsky, D, Oscier, D G, Strefford, J C

Get full text

Peri‐operative use of paracetamol by Oscier, C. D., Milner, Q. J. W.

“…Summary This article is a review of the peri‐operative use of paracetamol. It reviews the pharmacology of paracetamol, highlighting new information about the…”
Get full text

Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease by Rose-Zerilli, M J J, Gibson, J, Wang, J, Tapper, W, Davis, Z, Parker, H, Larrayoz, M, McCarthy, H, Walewska, R, Forster, J, Gardiner, A, Steele, A J, Chelala, C, Ennis, S, Collins, A, Oakes, C C, Oscier, D G, Strefford, J C

“…The biological features of IGHV-M chronic lymphocytic leukemia responsible for disease progression are still poorly understood. We undertook a longitudinal…”
Get full text

Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications by Bikos, V, Darzentas, N, Hadzidimitriou, A, Davis, Z, Hockley, S, Traverse-Glehen, A, Algara, P, Santoro, A, Gonzalez, D, Mollejo, M, Dagklis, A, Gangemi, F, Bosler, D S, Bourikas, G, Anagnostopoulos, A, Tsaftaris, A, Iannitto, E, Ponzoni, M, Felman, P, Berger, F, Belessi, C, Ghia, P, Papadaki, T, Dogan, A, Degano, M, Matutes, E, Piris, M A, Oscier, D, Stamatopoulos, K

“…We performed an immunogenetic analysis of 345 IGHV–IGHD–IGHJ rearrangements from 337 cases with primary splenic small B-cell lymphomas of marginal-zone origin…”
Get full text

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations by Zenz, T, Vollmer, D, Trbusek, M, Smardova, J, Benner, A, Soussi, T, Helfrich, H, Heuberger, M, Hoth, P, Fuge, M, Denzel, T, Häbe, S, Malcikova, J, Kuglik, P, Truong, S, Patten, N, Wu, L, Oscier, D, Ibbotson, R, Gardiner, A, Tracy, I, Lin, K, Pettitt, A, Pospisilova, S, Mayer, J, Hallek, M, Döhner, H, Stilgenbauer, S

“…The TP53 mutation profile in chronic lymphocytic leukemia (CLL) and the correlation of TP53 mutations with allele status or associated molecular genetics are…”
Get full text

Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference by Baliakas, Panagiotis, Puiggros, Anna, Xochelli, Aliki, Sutton, Lesley-Ann, Nguyen-Khac, Florence, Gardiner, Anne, Plevova, Karla, Minga, Eva, Hadzidimitriou, Anastasia, Walewska, Renata, McCarthy, Helen, Ortega, Margarita, Collado, Rosa, González, Teresa, Granada, Isabel, Luño, Elisa, Kotašková, Jana, Moysiadis, Theodoros, Davis, Zadie, Stavroyianni, Niki, Anagnostopoulos, Achilles, Strefford, Jonathan C, Pospisilova, Sarka, Davi, Frederic, Athanasiadou, Anastasia, Rosenquist, Richard, Oscier, David, Espinet, Blanca, Stamatopoulos, Kostas

Get full text

Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects by Pettitt, A R, Matutes, E, Oscier, D

Get full text

A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease by Best, O G, Gardiner, A C, Davis, Z A, Tracy, I, Ibbotson, R E, Majid, A, Dyer, M J S, Oscier, D G

Get full text